Insider Trading activities of Biocryst Pharmaceuticals Inc insiders.

Monthly summaries of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Biocryst Pharmaceuticals Inc since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Biocryst Pharmaceuticals Inc since year 2005. Table 2 shows the detailed insider transactions of Biocryst Pharmaceuticals Inc since 2005. The reporting company's ticker symbol is BCRX. The reporting company's CIK number is 882796.
The total value of stock buying since 2005 is $19,133,715.
The total value of stock sales since 2005 is $55,029,732.
The total value of stock option exercises since 2005 is $5,202,989.


Table 1. Monthly summaries of insider stock purchases, sales, and option exercises for Biocryst Pharmaceuticals Inc (BCRX).
Trading Period Insider Buying Insider Sales Option Exercises
year-month Shares Value Shares Value Shares Value
2017-11 0 $0 64,310 $303,543 0 $0
2017-09 0 $0 54,250 $294,035 54,250 $231,647
2017-05 0 $0 0 $0 7,750 $36,657
2017-03 0 $0 16,250 $139,781 52,705 $156,208
2016-12 0 $0 3,250 $24,212 3,250 $12,285
2016-09 0 $0 8,357 $35,684 0 $0
2016-08 0 $0 4,097,031 $20,843,199 0 $0
2016-02 252,715 $1,621,223 0 $0 0 $0
2016-01 540,040 $3,906,771 0 $0 58,464 $166,500
2015-12 0 $0 6,052 $64,614 0 $0
2015-07 0 $0 3,500 $57,750 33,868 $399,981
2015-06 0 $0 122,514 $1,812,373 103,514 $161,640
2015-05 0 $0 3,000 $33,000 0 $0
2015-03 0 $0 60,000 $629,249 0 $0
2015-02 10,000 $102,700 0 $0 0 $0
2015-01 0 $0 0 $0 100,000 $129,000
2014-12 0 $0 137,899 $1,706,770 81,000 $267,479
2014-08 0 $0 10,000 $135,800 10,000 $54,500
2014-07 0 $0 3,125 $40,625 29,580 $114,780
2014-06 0 $0 6,250 $76,531 27,478 $139,671
2014-05 0 $0 0 $0 58,102 $256,687
2014-03 0 $0 100,166 $1,259,252 93,032 $466,161
2014-02 0 $0 0 $0 23,179 $99,669
2014-01 0 $0 0 $0 48,725 $149,350
2013-11 3,000 $18,570 0 $0 0 $0
2013-08 1,136,364 $5,000,001 0 $0 0 $0
2013-05 0 $0 0 $0 196,007 $235,208
2013-03 3,000 $3,690 0 $0 0 $0
2012-12 20,000 $30,200 0 $0 0 $0
2012-06 20,000 $63,680 0 $0 0 $0
2012-03 2,000 $10,430 5,088 $24,318 0 $0
2012-02 0 $0 30,912 $130,448 84,580 $35,239
2012-01 0 $0 60,624 $148,528 60,624 $72,748
2011-12 0 $0 4,542 $12,944 0 $0
2011-11 10,000 $27,500 0 $0 0 $0
2011-08 10,000 $25,190 0 $0 0 $0
2011-05 10,000 $35,600 0 $0 0 $0
2011-03 10,000 $33,990 22,615 $76,777 65,000 $78,000
2010-08 0 $0 2,500 $15,500 2,500 $3,000
2010-06 0 $0 1,250 $8,712 1,250 $1,500
2010-05 0 $0 1,250 $9,600 1,250 $1,500
2010-04 0 $0 58,904 $482,054 58,904 $163,979
2010-03 0 $0 26,500 $187,486 26,500 $45,800
2010-02 5,000 $33,300 15,146 $104,779 15,146 $53,354
2010-01 0 $0 35,464 $253,247 4,166 $10,748
2009-12 0 $0 151,367 $1,220,917 4,167 $10,750
2009-11 0 $0 452,800 $4,370,514 0 $0
2009-10 0 $0 16,000 $158,958 0 $0
2009-09 0 $0 20,000 $182,719 0 $0
2009-07 0 $0 2,468 $18,198 1,500 $4,890
2009-06 0 $0 481,846 $1,867,150 0 $0
2009-05 0 $0 1,142,217 $5,009,910 0 $0
2009-03 40,000 $48,880 0 $0 0 $0
2009-01 9,000 $14,535 0 $0 0 $0
2008-12 55,000 $81,400 0 $0 0 $0
2008-11 940,229 $951,238 0 $0 0 $0
2008-08 13,240 $38,996 0 $0 0 $0
2008-07 1,709 $4,822 0 $0 0 $0
2008-01 4,339 $15,195 0 $0 0 $0
2007-09 0 $0 20,000 $240,000 20,000 $127,500
2007-08 841,438 $6,583,646 0 $0 0 $0
2007-07 5,122 $36,134 0 $0 0 $0
2007-02 0 $0 0 $0 16,171 $72,898
2007-01 1,407 $12,161 0 $0 0 $0
2006-09 0 $0 5,600 $57,148 5,600 $26,096
2006-08 1,285 $11,565 0 $0 0 $0
2006-07 744 $7,209 0 $0 0 $0
2006-05 44,563 $316,089 26,243 $397,870 0 $0
2006-04 0 $0 10,000 $180,240 10,684 $174,950
2006-03 0 $0 184,162 $3,778,215 198,846 $1,193,127
2006-02 0 $0 19,200 $318,411 6,167 $40,363
2006-01 0 $0 0 $0 1,512 $9,124
2005-12 0 $0 566,667 $8,318,671 0 $0
2000-11 11,000 $99,000 0 $0 0 $0

Table 2. Detailed insider stock purchases, sales, and option exercises of Biocryst Pharmaceuticals Inc insiders (BCRX)
  Trade Date   Insider Name Trade Type     Shares       Price ($)   Value ($)
2017-11-13 Sheridan William P (Senior VP - CMO) Sale 64,310 4.72 303,543
2017-09-18 Cohen Fred E (Director) Sale 54,250 5.42 294,035
2017-09-18 Cohen Fred E (Director) Option Ex 54,250 4.27 231,647
2017-05-22 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 7,750 4.73 36,657
2017-03-20 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,250 9.20 29,899
2017-03-20 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,250 3.78 12,285
2017-03-16 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 36,455 2.60 94,783
2017-03-10 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,250 9.06 29,445
2017-03-10 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,250 3.78 12,285
2017-03-08 Staab Thomas R Ii (Senior Vice President and CFO) Sale 6,500 8.43 54,762
2017-03-08 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 6,500 3.78 24,570
2017-03-06 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,250 7.90 25,675
2017-03-06 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,250 3.78 12,285
2016-12-19 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,250 7.45 24,212
2016-12-19 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,250 3.78 12,285
2016-09-14 Barnes Alane P (VP, General Counsel & Corp Sec) Sale 8,357 4.27 35,684
2016-08-25 Babu Yarlagadda S (Senior VP - Drug Discovery) Sale 30,000 4.06 121,799
2016-08-16 Baker Felix (10% Owner) Sale 990 4.29 4,246
2016-08-15 Baker Felix (10% Owner) Sale 400,000 4.83 1,931,200
2016-08-12 Staab Thomas R Ii (Senior Vice President and CFO) Sale 4,558 5.22 23,792
2016-08-12 Baker Felix (10% Owner) Sale 3,645,600 5.13 18,690,991
2016-08-11 Staab Thomas R Ii (Senior Vice President and CFO) Sale 1,306 5.05 6,595
2016-08-09 Staab Thomas R Ii (Senior Vice President and CFO) Sale 14,577 4.43 64,576
2016-02-05 Baker Felix (10% Owner) Buy 45,000 6.33 284,670
2016-02-04 Baker Felix (10% Owner) Buy 24,800 6.65 164,920
2016-02-03 Baker Felix (10% Owner) Buy 91,187 6.29 573,292
2016-02-02 Baker Felix (10% Owner) Buy 91,728 6.52 598,341
2016-01-29 Barnes Alane P (VP, General Counsel & Corp Sec) Option Ex 19,368 1.42 27,502
2016-01-28 Baker Felix (10% Owner) Buy 25,000 6.88 172,025
2016-01-27 Baker Felix (10% Owner) Buy 63,345 6.98 441,958
2016-01-22 Baker Felix (10% Owner) Buy 3,200 7.00 22,390
2016-01-21 Baker Felix (10% Owner) Buy 103,600 7.29 755,347
2016-01-20 Stonehouse Jon P (President & CEO) Option Ex 24,096 4.15 99,998
2016-01-20 Baker Felix (10% Owner) Buy 52,695 6.91 363,911
2016-01-19 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 15,000 2.60 39,000
2016-01-19 Baker Felix (10% Owner) Buy 92,200 7.12 656,740
2016-01-15 Baker Felix (10% Owner) Buy 200,000 7.47 1,494,400
2015-12-21 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,052 10.86 33,144
2015-12-17 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,000 10.49 31,470
2015-07-20 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,500 16.50 57,750
2015-07-15 Stonehouse Jon P (President & CEO) Option Ex 33,868 11.81 399,981
2015-06-22 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,750 16.00 60,000
2015-06-22 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,750 4.73 17,737
2015-06-19 Barnes Alane P (VP, General Counsel & Corp Sec) Sale 3,000 15.00 45,000
2015-06-19 Sheridan William P (Senior VP - CMO) Sale 70,389 15.05 1,059,354
2015-06-19 Sheridan William P (Senior VP - CMO) Option Ex 70,389 1.20 84,466
2015-06-19 Stonehouse Jon P (President & CEO) Sale 20,000 15.02 300,400
2015-06-19 Stonehouse Jon P (President & CEO) Option Ex 20,000 1.20 24,000
2015-06-19 Staab Thomas R Ii (Senior Vice President and CFO) Sale 6,675 15.00 100,125
2015-06-19 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,175 3.78 12,001
2015-06-18 Staab Thomas R Ii (Senior Vice President and CFO) Sale 9,700 13.92 134,994
2015-06-18 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 6,200 3.78 23,436
2015-06-05 Staab Thomas R Ii (Senior Vice President and CFO) Sale 6,000 12.75 76,500
2015-06-01 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,000 12.00 36,000
2015-05-18 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,000 11.00 33,000
2015-03-19 Babu Yarlagadda S (Senior VP - Drug Discovery) Sale 12,105 10.16 122,986
2015-03-05 Babu Yarlagadda S (Senior VP - Drug Discovery) Sale 37,400 10.59 396,066
2015-03-04 Babu Yarlagadda S (Senior VP - Drug Discovery) Sale 10,495 10.50 110,197
2015-02-20 Hutson Nancy J (Director) Buy 10,000 10.27 102,700
2015-01-08 Cohen Fred E (Director) Option Ex 100,000 1.29 129,000
2014-12-30 Sheridan William P (Senior VP - CMO) Sale 23,104 12.06 278,634
2014-12-30 Sheridan William P (Senior VP - CMO) Option Ex 23,104 1.42 32,807
2014-12-29 Sheridan William P (Senior VP - CMO) Sale 105,295 12.43 1,308,816
2014-12-29 Sheridan William P (Senior VP - CMO) Option Ex 48,396 4.11 198,762
2014-12-29 Staab Thomas R Ii (Senior Vice President and CFO) Sale 9,500 12.56 119,320
2014-12-29 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 9,500 3.78 35,910
2014-08-27 Staab Thomas R Ii (Senior Vice President and CFO) Sale 10,000 13.58 135,800
2014-08-27 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 10,000 5.45 54,500
2014-07-25 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 26,455 3.78 99,999
2014-07-01 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,125 13.00 40,625
2014-07-01 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,125 4.73 14,781
2014-06-23 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,125 12.49 39,031
2014-06-23 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,125 4.73 14,781
2014-06-17 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,125 12.00 37,500
2014-06-17 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,125 4.73 14,781
2014-06-03 Sheridan William P (Senior VP - CMO) Option Ex 21,228 5.19 110,109
2014-05-22 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 17,685 3.78 66,849
2014-05-09 Stonehouse Jon P (President & CEO) Option Ex 40,417 4.70 189,838
2014-03-31 Abercrombie George B (Director) Option Ex 4,000 1.71 6,840
2014-03-14 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,125 11.24 35,125
2014-03-14 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,125 4.73 14,781
2014-03-06 Lee Kenneth B Jr (Director) Sale 12,665 12.69 160,718
2014-03-06 Lee Kenneth B Jr (Director) Option Ex 22,917 3.80 87,084
2014-03-04 Barnes Alane P (VP, General Counsel & Corp Sec) Sale 40,734 12.63 514,470
2014-03-04 Barnes Alane P (VP, General Counsel & Corp Sec) Option Ex 31,174 4.25 132,333
2014-03-04 Babu Yarlagadda S (Senior VP - Drug Discovery) Sale 40,642 12.57 510,869
2014-03-04 Babu Yarlagadda S (Senior VP - Drug Discovery) Option Ex 28,816 7.32 210,933
2014-03-04 Staab Thomas R Ii (Senior Vice President and CFO) Sale 3,000 12.69 38,070
2014-03-04 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 3,000 4.73 14,190
2014-02-24 Babu Yarlagadda S (Senior VP - Drug Discovery) Option Ex 23,179 4.30 99,669
2014-01-14 Barnes Alane P (VP, General Counsel & Corp Sec) Option Ex 13,500 1.20 16,200
2014-01-13 Staab Thomas R Ii (Senior Vice President and CFO) Option Ex 35,225 3.78 133,150
2013-11-12 Abercrombie George B (Director) Buy 3,000 6.19 18,570
2013-08-01 Baker Bros. Investments, L.p. (10% Owner) Buy 1,136,364 4.40 5,000,001
2013-05-28 Sheridan William P (SR VP - CMO) Option Ex 16,407 1.20 19,688
2013-05-23 Stonehouse Jon P (President & CEO) Option Ex 179,600 1.20 215,520
2013-03-05 Abercrombie George B (Director) Buy 3,000 1.23 3,690
2012-12-14 Jensen Peder (Director) Buy 20,000 1.51 30,200
2012-06-05 Jensen Peder (Director) Buy 20,000 3.18 63,680
2012-03-13 Sanders Charles A (Director) Buy 2,000 5.21 10,430
2012-03-02 Babu Yarlagadda S (VP Drug Discovery) Sale 837 4.78 4,000
2012-03-02 Sheridan William P (SR VP - CMO) Sale 956 4.78 4,569
2012-03-02 Mccullough David (VP) Sale 574 4.78 2,743
2012-03-02 Stonehouse Jon P (President & CEO) Sale 2,721 4.78 13,006
2012-02-29 Babu Yarlagadda S (VP Drug Discovery) Option Ex 53,668 .00 0
2012-02-22 Babu Yarlagadda S (VP Drug Discovery) Sale 30,912 4.22 130,448
2012-02-22 Babu Yarlagadda S (VP Drug Discovery) Option Ex 30,912 1.14 35,239
2012-01-03 Mccullough David (VP) Sale 60,624 2.45 148,528
2012-01-03 Mccullough David (VP) Option Ex 60,624 1.20 72,748
2011-12-07 Mccullough David (VP) Sale 4,542 2.85 12,944
2011-11-18 Jensen Peder (Director) Buy 10,000 2.75 27,500
2011-08-08 Stonehouse Jon P (President & CEO) Buy 10,000 2.52 25,190
2011-05-12 Jensen Peder (Director) Buy 10,000 3.56 35,600
2011-03-18 Stonehouse Jon P (President & CEO) Buy 10,000 3.40 33,990
2011-03-16 Grant Stuart (SR VP & CFO) Sale 22,615 3.40 76,777
2011-03-16 Grant Stuart (SR VP & CFO) Option Ex 65,000 1.20 78,000
2010-08-04 Grant Stuart (SR VP & CFO) Sale 2,500 6.20 15,500
2010-08-04 Grant Stuart (SR VP & CFO) Option Ex 2,500 1.20 3,000
2010-06-03 Grant Stuart (SR VP & CFO) Sale 1,250 6.97 8,712
2010-06-03 Grant Stuart (SR VP & CFO) Option Ex 1,250 1.20 1,500
2010-05-03 Grant Stuart (SR VP & CFO) Sale 1,250 7.68 9,600
2010-05-03 Grant Stuart (SR VP & CFO) Option Ex 1,250 1.20 1,500
2010-04-29 Grant Stuart (SR VP & CFO) Sale 36,990 8.31 307,386
2010-04-29 Grant Stuart (SR VP & CFO) Option Ex 36,990 3.26 120,587
2010-04-28 Grant Stuart (SR VP & CFO) Sale 1,563 8.26 12,910
2010-04-28 Grant Stuart (SR VP & CFO) Option Ex 1,563 3.26 5,095
2010-04-12 Grant Stuart (SR VP & CFO) Sale 509 8.26 4,204
2010-04-12 Grant Stuart (SR VP & CFO) Option Ex 509 3.26 1,659
2010-04-08 Sheridan William P (SR VP - CMO) Sale 18,593 8.01 148,855
2010-04-08 Sheridan William P (SR VP - CMO) Option Ex 18,593 1.89 35,140
2010-04-05 Grant Stuart (SR VP & CFO) Sale 1,249 6.96 8,699
2010-04-05 Grant Stuart (SR VP & CFO) Option Ex 1,249 1.20 1,498
2010-03-15 Horovitz Zola P (Director) Sale 10,000 7.21 72,150
2010-03-15 Horovitz Zola P (Director) Option Ex 10,000 2.60 26,000
2010-03-12 Mills Mike (Principal Accounting Officer) Sale 1,500 7.31 10,966
2010-03-12 Mills Mike (Principal Accounting Officer) Option Ex 1,500 1.20 1,800
2010-03-03 Grant Stuart (SR VP & CFO) Sale 15,000 6.96 104,370
2010-03-03 Grant Stuart (SR VP & CFO) Option Ex 15,000 1.20 18,000
2010-02-10 Mills Mike (Principal Accounting Officer) Sale 5,146 7.05 36,279
2010-02-10 Mills Mike (Principal Accounting Officer) Option Ex 5,146 3.80 19,554
2010-02-08 Sanders Charles A (Director) Buy 5,000 6.66 33,300
2010-02-01 Horovitz Zola P (Director) Sale 10,000 6.85 68,500
2010-02-01 Horovitz Zola P (Director) Option Ex 10,000 3.38 33,800
2010-01-22 Grant Stuart (SR VP & CFO) Sale 17,027 7.02 119,529
2010-01-22 Mccullough David (VP) Sale 14,271 7.02 100,182
2010-01-11 Sheridan William P (SR VP - CMO) Sale 4,166 8.05 33,536
2010-01-11 Sheridan William P (SR VP - CMO) Option Ex 4,166 2.58 10,748
2009-12-01 Sheridan William P (SR VP - CMO) Sale 4,167 8.17 34,044
2009-12-01 Sheridan William P (SR VP - CMO) Option Ex 4,167 2.58 10,750
2009-12-01 Featheringill William W (Director) Sale 147,200 8.06 1,186,873
2009-11-23 Featheringill William W (Director) Sale 13,800 9.56 131,969
2009-11-20 Featheringill William W (Director) Sale 439,000 9.65 4,238,545
2009-10-26 Babu Yarlagadda S (VP Drug Discovery) Sale 6,400 10.85 69,420
2009-10-21 Babu Yarlagadda S (VP Drug Discovery) Sale 200 10.00 2,000
2009-10-20 Babu Yarlagadda S (VP Drug Discovery) Sale 3,400 10.00 34,000
2009-10-14 Sheridan William P (SR VP - CMO) Sale 6,000 8.92 53,538
2009-09-23 Babu Yarlagadda S (VP Drug Discovery) Sale 20,000 9.14 182,719
2009-07-23 Mills Mike (Principal Accounting Officer) Sale 1,500 8.26 12,390
2009-07-23 Mills Mike (Principal Accounting Officer) Option Ex 1,500 3.26 4,890
2009-07-17 Mills Mike (Principal Accounting Officer) Sale 968 6.00 5,808
2009-06-01 Baker Felix (10% Owner) Sale 242,419 3.88 939,372
2009-05-29 Baker Felix (10% Owner) Sale 199,868 4.21 841,841
2009-05-28 Baker Felix (10% Owner) Sale 374,787 4.48 1,678,669
2009-03-12 Erck Stanley C (Director) Buy 40,000 1.22 48,880
2009-01-30 Sheridan William P (SR VP - CMO) Buy 3,000 1.61 4,845
2009-01-30 Grant Stuart (SR VP & CFO) Buy 3,000 1.61 4,845
2009-01-30 Stonehouse Jon P (President & CEO) Buy 3,000 1.61 4,845
2008-12-01 Stonehouse Jon P (President & CEO) Buy 55,000 1.48 81,400
2008-11-24 Baker Felix (10% Owner) Buy 10,000 .98 9,767
2008-11-21 Baker Felix (10% Owner) Buy 42,000 .91 38,386
2008-11-20 Baker Felix (10% Owner) Buy 410,278 1.00 410,278
2008-11-03 Stonehouse Jon P (President & CEO) Buy 25,000 1.75 43,625
2008-08-12 Stonehouse Jon P (President & CEO) Buy 2,300 3.10 7,123
2008-08-11 Stonehouse Jon P (President & CEO) Buy 7,700 2.95 22,730
2008-08-04 Grant Stuart (SR VP & CFO) Buy 3,000 2.82 8,466
2008-08-04 Stonehouse Jon P (President & CEO) Buy 240 2.82 677
2008-07-31 Darwin Michael A (Principal Accounting Officer) Buy 1,709 2.82 4,822
2008-01-31 Stonehouse Jon P (President & CEO) Buy 3,000 3.50 10,506
2008-01-31 Darwin Michael A (Principal Accounting Officer) Buy 1,339 3.50 4,689
2007-09-04 Bennett J Claude (Chief Operating Officer) Sale 20,000 12.00 240,000
2007-09-04 Bennett J Claude (Chief Operating Officer) Option Ex 20,000 6.38 127,500
2007-08-14 Stonehouse Jon P (President & CEO) Buy 2,650 9.86 26,129
2007-08-13 Stonehouse Jon P (President & CEO) Buy 7,250 9.87 71,521
2007-08-06 Featheringill William W Buy 831,538 7.80 6,485,996
2007-07-31 Stonehouse Jon P (CEO) Buy 2,463 7.05 17,376
2007-07-31 Nugent Jonathan M (VP Corp Communications) Buy 285 7.05 2,010
2007-07-31 Alexander W James (SR. VP, Chief Medical Officer) Buy 2,374 7.05 16,748
2007-02-26 Bennett J Claude (President) Option Ex 16,171 4.51 72,898
2007-01-31 Nugent Jonathan M (VP Corp Communications) Buy 223 8.64 1,927
2007-01-31 Riggs Randall B (Senior VP Business Development) Buy 1,184 8.64 10,234
2006-09-01 Nugent Jonathan M (VP Corp Communications) Sale 5,600 10.21 57,148
2006-09-01 Nugent Jonathan M (VP Corp Communications) Option Ex 5,600 4.66 26,096
2006-08-14 Alexander W James (SR. VP, Chief Medical Officer) Buy 1,285 9.00 11,565
2006-07-31 Riggs Randall B (Senior VP Business Development) Buy 744 9.69 7,209
2006-05-10 Bennett J Claude (President) Buy 6,563 6.50 42,659
2006-05-03 Bennett J Claude (President) Buy 35,000 6.50 227,500
2006-05-03 Bennett J Claude (President) Sale 26,243 15.16 397,870
2006-05-03 Seidenberg Beth C Buy 3,000 15.31 45,930
2006-04-03 Bennett J Claude (President) Sale 10,000 18.02 180,240
2006-04-03 Bennett J Claude (President) Option Ex 10,684 16.38 174,950
2006-03-15 Darwin Michael A (Chief Financial Officer) Sale 22,650 19.21 435,129
2006-03-15 Darwin Michael A (Chief Financial Officer) Option Ex 22,650 4.12 93,340
2006-03-03 Riggs Randall B (Senior VP Business Development) Sale 1,512 20.39 30,826
2006-03-03 Bennett J Claude (President) Sale 10,000 21.01 210,110
2006-03-03 Bennett J Claude (President) Option Ex 11,550 16.38 189,131
2006-03-03 Bugg Charles E (Chairman) Sale 100,000 20.68 2,068,100
2006-03-03 Bugg Charles E (Chairman) Option Ex 109,764 5.53 607,104
2006-02-13 Bennett J Claude (President) Sale 3,000 16.93 50,804
2006-02-13 Bennett J Claude (President) Option Ex 6,167 6.54 40,363
2006-02-10 Featheringill William W Sale 16,200 16.52 267,607
2006-01-31 Riggs Randall B (Senior VP Business D) Option Ex 1,512 6.04 9,124
2005-12-02 Gordon Carl L (Director) Sale 566,667 14.68 8,318,671
2000-11-02 Featheringill William W (Director) Buy 5,000 9.00 45,000
2000-11-01 Featheringill William W (Director) Buy 6,000 9.00 54,000

Insider trading activities including stock purchases, stock sales, and option exercises of BCRX listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Biocryst Pharmaceuticals Inc (symbol BCRX, CIK number 882796) see the Securities and Exchange Commission (SEC) website.